Eradication Of Human Cancer Cells By Antigen Specific Delivery Of Carbon Monxide With A Family Photoactivatable Antibobody Photocorm Conjugates

Background

PhotoCORMs are compounds that release Carbon monoxide (CO) upon exposure to light. CO released from photoCORMs exposed to light is known to cause apoptotic cell death and can sensitize human cancer cells to chemotherapeutics. Drug resistance is often encountered in cancer chemotherapy. In addition, efforts to minimize toxicity from chemotherapy have met with little success. A UC Santa Cruz researcher has developed a system to specifically deliver photoCORMs to tumors and presensitize those tumors to conventional chemotherapy

Technology Description

The invention involves an an antibody-based, targeted treatment that precisely targets CO to tumors to increase efficacy in chemotherapeutics with no toxic effects. Ab-photoCORMS,  deliver cytotoxic levels of CO to ovarian cancer after exposure to low visible light in sufficient quantities to affect cell viability. Effects are seen after a 24 hour incubation. 

Applications

Antibody targeted cancer therapy

Advantages

• CO pretreatment potentially results in lower dose chemotherapy
• Targeted CO results in greater effectiveness  

Intellectual Property Information

Related Materials

• Diminished viability of human ovarian cancer cells by antigen-specific delivery of carbon monoxide with a family of photoactivatable antibody-photoCORM conjugates - 11/20/2019